BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 29441568)

  • 1. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K
    Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
    Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
    PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia.
    Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Greuter MJE; Coupé VMH; Canfell K
    Cancer Epidemiol Biomarkers Prev; 2018 Dec; 27(12):1450-1461. PubMed ID: 30190276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model.
    Knudsen AB; Hur C; Gazelle GS; Schrag D; McFarland EG; Kuntz KM
    Ann Intern Med; 2012 Nov; 157(9):611-20. PubMed ID: 23128861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population.
    Knudsen AB; Lansdorp-Vogelaar I; Rutter CM; Savarino JE; van Ballegooijen M; Kuntz KM; Zauber AG
    J Natl Cancer Inst; 2010 Aug; 102(16):1238-52. PubMed ID: 20664028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations.
    Vanness DJ; Knudsen AB; Lansdorp-Vogelaar I; Rutter CM; Gareen IF; Herman BA; Kuntz KM; Zauber AG; van Ballegooijen M; Feuer EJ; Chen MH; Johnson CD
    Radiology; 2011 Nov; 261(2):487-98. PubMed ID: 21813740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy.
    O'Leary BA; Olynyk JK; Neville AM; Platell CF
    J Gastroenterol Hepatol; 2004 Jan; 19(1):38-47. PubMed ID: 14675241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
    Sonnenberg A; Delcò F; Inadomi JM
    Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test.
    Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N
    J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.
    Sharp L; Tilson L; Whyte S; O'Ceilleachair A; Walsh C; Usher C; Tappenden P; Chilcott J; Staines A; Barry M; Comber H
    Br J Cancer; 2012 Feb; 106(5):805-16. PubMed ID: 22343624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force.
    Knudsen AB; Zauber AG; Rutter CM; Naber SK; Doria-Rose VP; Pabiniak C; Johanson C; Fischer SE; Lansdorp-Vogelaar I; Kuntz KM
    JAMA; 2016 Jun; 315(23):2595-609. PubMed ID: 27305518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
    Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
    PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of screening strategies for colorectal cancer.
    Barzi A; Lenz HJ; Quinn DI; Sadeghi S
    Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests.
    Lucidarme O; Cadi M; Berger G; Taieb J; Poynard T; Grenier P; Beresniak A
    Eur J Radiol; 2012 Jul; 81(7):1413-9. PubMed ID: 21444171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of Colorectal Cancer Screening Strategies.
    Patel SS; Kilgore ML
    Cancer Control; 2015 Apr; 22(2):248-58. PubMed ID: 26068773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests.
    Peterse EFP; Meester RGS; de Jonge L; Omidvari AH; Alarid-Escudero F; Knudsen AB; Zauber AG; Lansdorp-Vogelaar I
    J Natl Cancer Inst; 2021 Feb; 113(2):154-161. PubMed ID: 32761199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of colorectal cancer screening methods in Iran.
    Allameh Z; Davari M; Emami MH
    Arch Iran Med; 2011 Mar; 14(2):110-4. PubMed ID: 21361717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of colorectal cancer screening - an overview.
    Lansdorp-Vogelaar I; Knudsen AB; Brenner H
    Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):439-49. PubMed ID: 20833348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.